Blood Advances
ISSN: 2473-9529
eISSN: 2476-9537
Publisher: American Society of Hematology
Publications (27)
Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL (2023)
Blumenberg V, Busch G, Baumann S, Jitschin R, Iacoboni G, Gallur L, Iraola-Truchuelo J, et al.
Journal article
Neutrophil transit time and localization within the megakaryocyte define morphologically distinct forms of emperipolesis (2022)
Huang FY, Cunin P, Radtke FA, Darbousset R, Grieshaber-Bouyer R, Nigrovic PA
Journal article
Junctional adhesion molecule C expression specifies a CD138low/neg multiple myeloma cell population in mice and humans (2022)
Brandl A, Solimando AG, Mokhtari Z, Tabares P, Medler J, Manz H, Da Via MC, et al.
Journal article
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study (2022)
Middeke JM, Metzeler KH, Rollig C, Kramer M, Eckardt JN, Stasik S, Greif PA, et al.
Journal article
Bone marrow stroma cells promote induction of a chemoresistant and prognostic unfavorable S100A8/A9high AML cell subset. (2022)
Böttcher M, Panagiotidis K, Bruns H, Stumpf M, Völkl S, Geyh S, Dietel B, et al.
Journal article
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. (2022)
Etra A, Gergoudis S, Morales G, Spyrou N, Shah J, Kowalyk S, Ayuk F, et al.
Journal article
Human iPSC-derived macrophages for efficient Staphylococcus aureus clearance in a murine pulmonary infection model (2021)
Hashtchin AR, Fehlhaber B, Hetzel M, Manstein F, Stalp JL, Glage S, Abeln M, et al.
Journal article
Single- And double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MM (2021)
Truger MS, Duell J, Zhou X, Heimeshoff L, Ruckdeschel A, John M, Riedel A, et al.
Journal article
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia (2021)
Stasik S, Eckardt JN, Kramer M, Roellig C, Kraemer A, Scholl S, Hochhaus A, et al.
Journal article
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas (2021)
Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker F, et al.
Journal article